Deutsche Bank Maintains Hold on Alvotech, Raises Price Target to $12
Deutsche Bank analyst Emmanuel Papadakis maintains Alvotech (NASDAQ:ALVO) with a Hold and raises the price target from $8 to $12.
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell
• Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair
Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy.
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers IsoPlexis (NASDAQ:ISO) stock moved upwards by 131.1% to $1.59 during Thursday’s regular session. Trading volume for IsoPlexis’s…
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones dropping over 400 points on Thursday. Here are some big stocks recording gains in today’s session.
Alvotech Provides Update On U.S. Regulatory Status Of AVT02, Co’s Proposed High-Concentration, Interchangeable Biosimilar To Humira
U.S. Food and Drug Administration (FDA) has confirmed that the goal date for an approval decision on Alvotech's license application for AVT02 is April 13, 2023
FDA has completed review of
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC met the primary endpoint.
Alvotech Secures Financing Facilities Of ~$136M
Existing senior bonds upsized by $70 million with additional investment from a consortium of institutional investors
Alvotech acquires the Reykjavik manufacturing facility, previously utilized
Reported Early Wednesday, Alvotech 9Months EPS $(1.00) Up From $(3.48) YoY, Sales $59.20M Up From $2.00M YoY
Revenue for first nine months of 2022 increased to $59.2 million, compared to $2.0 million for the same period in 2021